Corporate Overview

img

Alzheimer's Disease Facts and Figures

Alzamend Neuro™, Inc., (“Alzamend™)” is a Delaware corporation with its corporate headquarters in Tampa, Florida with nexus in California. The mission of Alzamend Neuro™ is to help the Alzheimer’s community by supporting the full product development life cycle of treatment and cures for Alzheimer’s Disease (“AD”) driven by the belief that strong support of research is the foundation for true innovation. The Company is providing hope through the commercialization of existing patented intellectual properties and know-how while simultaneously funding future treatments for other neurodegenerative diseases and psychiatric disorders, through advanced research and development.

Alzamend Neuro™ is currently working to transition two therapeutics targeting Alzheimer’s disease (“AD”) and psychiatric disorders from the research and preclinical stage into clinical stage and towards full commercialization. Our lead candidate, AL001, is a patented ionic co-crystal technology delivering a therapeutic combination of lithium, proline and salicylate, as a treatment of agitation and other possible symptoms in patients with indication of Alzheimer’s disease and psychiatric disorders. Our second candidate, AL002, is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that reduces beta-amyloid plaque and seeks to restore the ability of the patient’s immunological system to combat Alzheimer’s disease. There are no profound treatments today for Alzheimer’s disease and psychiatric disorders. With AL001 and AL002, the Company believes that we can change that.

Our Leadership

Stephan Jackman

Chief Executive Officer of Alzamend Neuro 20+ years multi-industry experience, specialized in Biotech and Pharmaceutical LEARN MORE

Kenneth S Cragun

Chief Financial Officer 30+ Years SEC reporting, Nasdaq CFO, multi-industry experience, including Biotech and Healthcare LEARN MORE

Henry Nisser

Executive Vice President and General Counsel 20+ years experience, U.S. securities compliance, M&A, equity/debt financings and corporate governance LEARN MORE

David J. Katzoff

Chief Operating Officer 30+ Years multi-industry experience, including Healthcare and Technology LEARN MORE

Our Board of Directors

Milton C Ault, III

Founder/Executive Chairman of Alzamend, Chairman and Chief Executive Officer of DPW Holdings 27+ years Financial Industry experience, seasoned Wall Street CEO & activist investor LEARN MORE

Stephan Jackman

Chief Executive Officer of Alzamend Neuro 20+ years multi-industry experience, specialized in Biotech and Pharmaceutical LEARN MORE

William B. Horne

President of DPW Holdings 25+ years Financial Industry experience, prior “Big 4” auditor & healthcare executive. LEARN MORE

Henry Nisser

Executive Vice President and General Counsel 20+ years experience, U.S. securities compliance, M&A, equity/debt financings and corporate governance LEARN MORE

Philip E. Mansour

Chief Executive Officer of MTIX International 25+ years multi-industry experience, seasoned executive, manager & coach LEARN MORE

Our Scientific Advisory Board

Eric M. McDade, DO

Associate Director of the DIAN Trials Unit and Clinical Trials Leadership at Washington University School of Medicine Associate Professor of Neurology, Washington University School of Medicine 157+ Peer-Reviewed Journal Publications LEARN MORE

Thomas M. Wisniewski, MD

Director of NYU Langone’s Pearl I. Barlow Center for Memory Evaluation and Treatment 300+ Peer-Reviewed Medical Journal Publications (19 U.S. Patents Issued) Leads a Research Laboratory Continuously Funded by the National Institutes of Health for 20+ Years LEARN MORE